AstraZeneca launches a $2bn overhaul to save $1.5bn a year but declines to say whether UK jobs are at risk
AstraZeneca's oncology, rare disease and respiratory divisions secured 47 project approvals in the first nine months of 2026, as third-quarter revenue rose seven per cent to $16.2bn.
Chief executive Pascal Soriot insisted AstraZeneca has "multiple potential blockbuster" drugs in late-stage development and remains on track for its $80bn annual revenue target by 2030.
The Cambridge-headquartered firm employs around 10,000 UK workers across sites including Macclesfield, London and Liverpool's Speke.
CFO Aradhana Sarin said the 'Reshaping for Sustainable Growth' programme is a reallocation, not a shrinkage: 'Overall we do not expect to shrink the headcount.'
Shares jumped 3.1% to £134.50 on Friday as investors cheered Q3 revenue of $16.2bn, beating City forecasts.
